Jan Spanholtz

2.2k total citations
40 papers, 1.5k citations indexed

About

Jan Spanholtz is a scholar working on Immunology, Oncology and Hematology. According to data from OpenAlex, Jan Spanholtz has authored 40 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 36 papers in Immunology, 25 papers in Oncology and 12 papers in Hematology. Recurrent topics in Jan Spanholtz's work include Immune Cell Function and Interaction (35 papers), CAR-T cell therapy research (24 papers) and T-cell and B-cell Immunology (20 papers). Jan Spanholtz is often cited by papers focused on Immune Cell Function and Interaction (35 papers), CAR-T cell therapy research (24 papers) and T-cell and B-cell Immunology (20 papers). Jan Spanholtz collaborates with scholars based in Netherlands, United States and Germany. Jan Spanholtz's co-authors include Harry Dolstra, Marleen Tordoir, Nicolaas Schaap, Tanja D. de Gruijl, Hans van Vliet, Frank Preijers, Henk M.W. Verheul, John P. Veluchamy, Nina Kok and Jos Paardekooper and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Jan Spanholtz

36 papers receiving 1.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jan Spanholtz Netherlands 23 1.2k 922 317 281 109 40 1.5k
Srinivas S. Somanchi United States 15 1.1k 0.9× 880 1.0× 195 0.6× 224 0.8× 102 0.9× 30 1.3k
Felix S. Lichtenegger Germany 18 698 0.6× 684 0.7× 440 1.4× 428 1.5× 109 1.0× 35 1.3k
Laura E. Bendzick United States 15 1.1k 0.9× 973 1.1× 110 0.3× 435 1.5× 108 1.0× 27 1.5k
Melissa M. Berrien-Elliott United States 19 1.5k 1.3× 1.0k 1.1× 253 0.8× 339 1.2× 73 0.7× 49 1.9k
Bartosz Grzywacz United States 14 960 0.8× 597 0.6× 266 0.8× 204 0.7× 38 0.3× 31 1.2k
Mobin Karimi United States 11 524 0.4× 414 0.4× 198 0.6× 291 1.0× 71 0.7× 32 927
Weiqing Jing United States 15 479 0.4× 452 0.5× 248 0.8× 225 0.8× 63 0.6× 29 825
May Daher United States 16 629 0.5× 631 0.7× 126 0.4× 275 1.0× 102 0.9× 38 1.0k
Paul W. Eldridge United States 14 750 0.6× 627 0.7× 361 1.1× 235 0.8× 173 1.6× 23 1.1k
Christina Krupka Germany 13 594 0.5× 861 0.9× 502 1.6× 398 1.4× 113 1.0× 25 1.3k

Countries citing papers authored by Jan Spanholtz

Since Specialization
Citations

This map shows the geographic impact of Jan Spanholtz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jan Spanholtz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jan Spanholtz more than expected).

Fields of papers citing papers by Jan Spanholtz

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jan Spanholtz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jan Spanholtz. The network helps show where Jan Spanholtz may publish in the future.

Co-authorship network of co-authors of Jan Spanholtz

This figure shows the co-authorship network connecting the top 25 collaborators of Jan Spanholtz. A scholar is included among the top collaborators of Jan Spanholtz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jan Spanholtz. Jan Spanholtz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Kok, Nina, Didem Özkazanç, Simar Pal Singh, et al.. (2025). CD28 signaling domain boosts persistence and in vivo anti-tumor activity of stem cell-derived CD19-CAR-NK cells. iScience. 28(6). 112548–112548.
2.
3.
4.
Vliet, A.A. van, C.D. Forbes, Jurriaan B. Tuynman, et al.. (2024). Allogeneic NK cells induce the in vitro activation of monocyte-derived and conventional type-2 dendritic cells and trigger an inflammatory response under cancer-associated conditions. Clinical & Experimental Immunology. 216(2). 159–171. 4 indexed citations
5.
Raimo, Monica, Susan Gibbs, Tanja D. de Gruijl, et al.. (2023). Early TRAIL-engagement elicits potent multimodal targeting of melanoma by CD34+ progenitor cell-derived NK cells. iScience. 26(7). 107078–107078. 4 indexed citations
6.
Georgoudaki, Anna‐Maria, Haiping Liu, Didem Özkazanç, et al.. (2022). Natural killer cells in clinical development as non-engineered, engineered, and combination therapies. Journal of Hematology & Oncology. 15(1). 164–164. 107 indexed citations
7.
Sheikhi, Abdolkarim, et al.. (2021). Natural Killer Cells and Anti-Cancer Therapies: Reciprocal Effects on Immune Function and Therapeutic Response. Cancers. 13(4). 711–711. 25 indexed citations
8.
Sheikhi, Abdolkarim, Roeland Lameris, Lisa A. King, et al.. (2021). Enhancement of NK Cell Antitumor Effector Functions Using a Bispecific Single Domain Antibody Targeting CD16 and the Epidermal Growth Factor Receptor. Cancers. 13(21). 5446–5446. 17 indexed citations
9.
Saha, Tanmoy, Chunxiao Cui, Arpita Kulkarni, et al.. (2021). Boosting Natural Killer Cell Therapies in Glioblastoma Multiforme Using Supramolecular Cationic Inhibitors of Heat Shock Protein 90. Frontiers in Molecular Biosciences. 8. 754443–754443. 9 indexed citations
10.
Geerts, Dirk, et al.. (2020). Genetic Engineering of Natural Killer Cells for Enhanced Antitumor Function. Frontiers in Immunology. 11. 607131–607131. 22 indexed citations
11.
Veluchamy, John P., Silvia Lopez‐Lastra, Jan Spanholtz, et al.. (2017). In Vivo Efficacy of Umbilical Cord Blood Stem Cell-Derived NK Cells in the Treatment of Metastatic Colorectal Cancer. Frontiers in Immunology. 8. 87–87. 38 indexed citations
12.
Veluchamy, John P., Nina Kok, Hans van Vliet, et al.. (2017). The Rise of Allogeneic Natural Killer Cells As a Platform for Cancer Immunotherapy: Recent Innovations and Future Developments. Frontiers in Immunology. 8. 631–631. 148 indexed citations
13.
Veluchamy, John P., A. Marijne Heeren, Jan Spanholtz, et al.. (2016). High-efficiency lysis of cervical cancer by allogeneic NK cells derived from umbilical cord progenitors is independent of HLA status. Cancer Immunology Immunotherapy. 66(1). 51–61. 29 indexed citations
14.
Spanholtz, Jan, et al.. (2014). IL-12 Directs Further Maturation of Ex Vivo Differentiated NK Cells with Improved Therapeutic Potential. PLoS ONE. 9(1). e87131–e87131. 33 indexed citations
15.
Thordardottir, Soley, Basav N. Hangalapura, Marta Cossu, et al.. (2013). The Aryl Hydrocarbon Receptor Antagonist StemRegenin 1 Promotes Human Plasmacytoid and Myeloid Dendritic Cell Development from CD34 + Hematopoietic Progenitor Cells. Stem Cells and Development. 23(9). 955–967. 57 indexed citations
16.
Cany, Jeannette, Anniek B. van der Waart, Marleen Tordoir, et al.. (2013). Natural Killer Cells Generated from Cord Blood Hematopoietic Progenitor Cells Efficiently Target Bone Marrow-Residing Human Leukemia Cells in NOD/SCID/IL2Rgnull Mice. PLoS ONE. 8(6). e64384–e64384. 76 indexed citations
17.
Spanholtz, Jan, Marleen Tordoir, Karoline Lipnik, et al.. (2012). Ex Vivo Generated Natural Killer Cells Acquire Typical Natural Killer Receptors and Display a Cytotoxic Gene Expression Profile Similar to Peripheral Blood Natural Killer Cells. Stem Cells and Development. 21(16). 2926–2938. 26 indexed citations
18.
Ahn, Yong‐Oon, Jan Spanholtz, Hongbo Wang, et al.. (2011). Natural Killer Cell Differentiation from Hematopoietic Stem Cells: A Comparative Analysis of Heparin- and Stromal Cell–Supported Methods. Biology of Blood and Marrow Transplantation. 18(4). 536–545. 25 indexed citations
19.
Spanholtz, Jan, Marleen Tordoir, Diana Eissens, et al.. (2010). High Log-Scale Expansion of Functional Human Natural Killer Cells from Umbilical Cord Blood CD34-Positive Cells for Adoptive Cancer Immunotherapy. PLoS ONE. 5(2). e9221–e9221. 142 indexed citations
20.
Levetzow, Gregor von, Jan Spanholtz, Julia Beckmann, et al.. (2006). Nucleofection, an Efficient Nonviral Method to Transfer Genes into Human Hematopoietic Stem and Progenitor Cells. Stem Cells and Development. 15(2). 278–285. 28 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Srinivas S. Somanchi Breakdown of academic impact, for papers by Felix S. Lichtenegger Breakdown of academic impact, for papers by Laura E. Bendzick Breakdown of academic impact, for papers by Melissa M. Berrien-Elliott Breakdown of academic impact, for papers by Bartosz Grzywacz Breakdown of academic impact, for papers by Mobin Karimi Breakdown of academic impact, for papers by Weiqing Jing Breakdown of academic impact, for papers by May Daher Breakdown of academic impact, for papers by Paul W. Eldridge Breakdown of academic impact, for papers by Christina Krupka
Rankless by CCL
2026